On December 24, 2025, Truist Securities reaffirmed a Buy recommendation for Agios Pharmaceuticals (NasdaqGS:AGIO), projecting a 12.72% upside from its latest closing price of $29.07 per share. The average one-year price target is $32.77, with estimates ranging from $20.20 to $50.40.
Agios Pharmaceuticals is projected to generate annual revenue of $137 million, marking a significant increase of 206.18%. The annual non-GAAP EPS is estimated at -6.53. Notably, institutional ownership has risen, with 472 funds reporting positions, an increase of 1.29% in the last quarter, and total institutional shares rising by 2.50% to 70,672K shares.
Farallon Capital Management, the largest shareholder, holds 5,781K shares (9.91% ownership), while Bellevue Group and Erste Asset Management have increased their stakes by 17.72% and 61.12%, respectively, in recent months.
